Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAC: Autologous HSCT for Crohn's Disease
NCT04154735Phase 2Withdrawn
- Sponsor
- Northwestern University
- Start
- Nov 2019
- Primary completion
- Mar 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous hematopoietic stem cells in Crohn's disease, sponsored by Northwestern University. Primary endpoints: Treatment-related mortality at 3 years, Overall survival at 3 years and 2 more. Planned start Nov 2019; status: withdrawn.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04154735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154735.